Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Deferred Revenue (2018 - 2022)

Ani Pharmaceuticals' Current Deferred Revenue history spans 8 years, with the latest figure at $100000.0 for Q1 2022.

  • For Q1 2022, Current Deferred Revenue changed 0.0% year-over-year to $100000.0; the TTM value through Mar 2022 reached $100000.0, changed 0.0%, while the annual FY2021 figure was $87000.0, 13.0% down from the prior year.
  • Current Deferred Revenue for Q1 2022 was $100000.0 at Ani Pharmaceuticals, up from $87000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $735000.0 in Q3 2018 and bottomed at $87000.0 in Q4 2021.
  • The 5-year median for Current Deferred Revenue is $112000.0 (2020), against an average of $316066.7.
  • The largest annual shift saw Current Deferred Revenue tumbled 82.08% in 2020 before it changed 0.0% in 2021.
  • A 5-year view of Current Deferred Revenue shows it stood at $711000.0 in 2018, then decreased by 29.68% to $500000.0 in 2019, then crashed by 80.0% to $100000.0 in 2020, then dropped by 13.0% to $87000.0 in 2021, then increased by 14.94% to $100000.0 in 2022.
  • Per Business Quant, the three most recent readings for ANIP's Current Deferred Revenue are $100000.0 (Q1 2022), $87000.0 (Q4 2021), and $100000.0 (Q3 2021).